Medical/Pharmaceuticals

RedHill Biopharma Reports Further Analysis of Phase 2/3 Data Including a 62% Reduction in Mortality with Oral Opaganib in Moderately Severe COVID-19 Patients

TEL AVIV, Israel and RALEIGH, N.C., Oct. 4, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today reported new data from the opaganib global Phase 2/3 study in hospitalized patien...

2021-10-04 21:24 12207

Debiopharm Encourages Breakthrough Cancer Research in Japan Through its Competitive JCA Mauvernay Award

LAUSANNE, Switzerland, Oct. 4, 2021 /PRNewswire/ -- Debiopharm ( www.debiopharm.com ), a Swiss-based global biopharmaceutical company, today announced the two winners of the 17th annual JCA Mauvernay Award for breakthrough Japanese oncology research projects in 2 categ...

2021-10-04 15:00 2126

New Research in Kosovo Highlights Connection Between Children's Poor Vision and Learning and Development

Study underscores link between uncorrected poor vision and children's potential DALLAS, Oct. 4, 2021 /PRNewswire/ -- A new study, a collaboration of  the Vision Impact Institute, EdGuard Institute, and ESSILOR's Vision for Life™ social impact fund, offers new insight into the correlation between ...

2021-10-04 12:30 3021

Chiranya Prachaseri recognized as Asia's Most Inspiring Executives

BANGKOK, Oct. 4, 2021 /PRNewswire/ -- "As recognized by the ACES Awards 2021 for theAsia's Most Inspiring Executives award, it is such a great honor not only me but also everyone in Cryoviva for being a team player and builder together", said Chiranya Prachaseri, Chief Executive Officer of Cryovi...

2021-10-04 10:30 3616

Brii Bio Presents Positive Phase 3 Data on BRII-196/BRII-198, the Company's SARS-CoV-2 Monoclonal Neutralizing Antibody Combination Therapy, in an Oral Late-Breaker Presentation at IDWeek 2021

DURHAM, N.C.and BEIJING, Oct. 4, 2021 /PRNewswire/ -- Brii Biosciences  Limited ("Brii Bio" or the "Company", stock code: 2137.HK) a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public health ...

2021-10-04 08:00 4752

Colorectal cancer diagnoses dropped over 40% during COVID-19 pandemic, new study shows

VIENNA, Oct. 4, 2021 /PRNewswire/ -- The number of colorectal cancer (CRC) cases diagnosed fell dramatically by 40% in a year during the COVID-19 pandemic, new research presented today at UEG Week Virtual 2021 has shown. The research, which was conducted across multiple hospitals in Spain, compa...

2021-10-04 06:00 2819

In Lead-up to Breast Cancer Awareness Month, New Hologic Global Women's Health Index Finds Globally Most Women Were Not Checked for Any Cancer in Past Year

Worldwide, 88% of women said in 2020 that they had not been tested for any type of cancer in the past 12 months. Most women believe checkups help improve health, but 40% haven't talked to a healthcare professional in the past 12 months. WASHINGTON, Oct. 2, 2021 /PRNewswire/ -- In the lead-up to ...

2021-10-02 12:18 3923

World's Leading Neuroscientists Unveil Research on COVID-19's Impact on the Brain, Understanding Migraine Pathophysiology, Solving the Mystery of Sleep, Biomarkers in Traumatic Brain Injury and More at 25th Biennial World Congress of Neurology from October 3-7

LONDON, Oct. 2, 2021 /PRNewswire/ -- The impact COVID-19 has on the brain, understanding migraine pathophysiology, solving the mystery of sleep by "Lighting Up the Brain," blood biomarkers for traumatic brain injury and more groundbreaking research will be unveiled by the world's leading neurosci...

2021-10-02 12:10 4930

CStone presents ARROW study data for GAVRETO® (pralsetinib) in Chinese patients with RET-mutant medullary thyroid cancer (MTC) for the first time in a late breaking oral abstract session at the 90th Annual Meeting of the American Thyroid Association 2021

* Primary efficacy results showed GAVRETO had robust and durable anti-tumor activity in the Chinese patients with advanced or metastatic RET-mutant medullary thyroid cancer (MTC), with a confirmed objective response rate (ORR) of 73.1%. And the 9-month duration of response (DOR) rate was 100% ...

2021-10-02 08:30 10447

Medidata Veterans Rama Kondru and Sastry Chilukuri Named co-CEOs

SINGAPORE and SYDNEY, Oct. 1, 2021 /PRNewswire/ -- Medidata, a Dassault Systèmes company, recently namedRama Kondru and Sastry Chilukuri co-CEOs. Both are Medidata veteran...

2021-10-01 09:00 4079

Fullerton Health Focuses on ASEAN in its Growth Strategy

SINGAPORE, Sept. 30, 2021 /PRNewswire/ -- Fullerton Health Corporation (FHC), Asia Pacific's leading vertically integrated healthcare platform has set its sights on growth inSoutheast Asia (ASEAN). ASEAN is the world's third most populous economy. By 2030, population will reach 723 million and th...

2021-09-30 22:25 5649

NCCN Publishes New Guide to Improving Knowledge and Quality of Life for Small Cell Lung Cancer Patients

New patient and caregiver resource from the National Comprehensive Cancer Network provides free expert consensus information on improving outcomes for people with an aggressive type of lung cancer. PLYMOUTH MEETING, Pa., Sept. 30, 2021 /PRNewswire/ -- The National Comprehensive Cancer Network® ...

2021-09-30 22:17 2964

CBMG Holdings Completes $120 Million in Series A Funding, Accelerating Development of CAR-T Therapy Pipelines and R&D for Innovative Solid Tumor Therapies

HONG KONG, Sept. 30, 2021 /PRNewswire/ -- CBMG Holdings (or the "Company"), a Cayman Island biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer and degenerative diseases, today announced the closing of a $120 million Series A investment, led by As...

2021-09-30 22:06 5085

Broncus Completed the First-in-man Clinical Trial of Its Targeted Lung Denervation Radiofrequency Ablation System

HONG KONG, Sept. 30, 2021 /PRNewswire/ -- Broncus Holding Corporation ("Broncus" or the "Company") is pleased to announce that it has completed the first-in-man clinical trial of its Targeted Lung Denervation (TLD) radiofrequency ablation system, which is expected to benefit patients with chroni...

2021-09-30 19:40 3757

Honda Prize 2021 Awarded to French Neurosurgeon and Physicist Dr. Alim Louis Benabid

TOKYO, Sept. 30, 2021 /PRNewswire/ -- The Honda Foundation, the public interest incorporated foundation established bySoichiro Honda and his younger brother Benjiro and currently led by PresidentHiroto Ishida, is pleased to announce that the Honda Prize 2021 will be awarded to Dr.Alim Louis Benab...

2021-09-30 16:00 2316

Zantrene® kills melanoma cancer cells that overproduce FTO

* Zantrene® at low concentrations kills high FTO producing melanoma cancer cells * Sensitivity to Zantrene® correlates with FTO levels, where high FTO producing cells show up to 60x greater sensitivity than low FTO producing cells * Results are highly supportive of future clinical trials in ...

2021-09-30 11:58 11399

Innovent Announces the First Patient Dosed in the Phase I/II Study of IBI351 (KRAS G12C inhibitor) in Patients with Advanced Malignant Tumors

SAN FRANCISCO and SUZHOU, China, Sept. 30, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major disea...

2021-09-30 08:00 4347

Nanoform receives funding to solve challenges for global health

HELSINKI, Sept. 29, 2021 /PRNewswire/ -- Nanoform, an innovative nanoparticle medicine enabling company, announces that Proof of Concept studies will be funded by the Bill & Melinda Gates Foundation to assess the added value Nanoform's award-winning CESS® nanoparticle engineering technology can d...

2021-09-29 21:15 2251

New Accedian Research Finds 76% of Manufacturers Plan to Use Private 5G by 2024

MONTREAL, Canada, Sept. 29, 2021 /PRNewswire/ -- Accedian, a leader in performance analytics, cybersecurity threat detection and end user experience solutions, today released new analyst research on the future of 5G in manufacturing. Conducted in partnership with Analysys Mason, a leading manage...

2021-09-29 21:07 2337

Recbio and Rhegen Signed an mRNA Vaccine Cooperation Agreement

TAIZHOU, China, Sept. 29, 2021 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (referred to as "Recbio") and Shenzhen Rhegen Biotechnology Co., Ltd. (referred to as "Rhegen Bio") recently signed a joint venture agreement to establish a joint venture company "Wuhan Rhecogen Biotechnology Co., ...

2021-09-29 19:37 4182
1 ... 375376377378379380381 ... 383